STOCK TITAN
  1. Home
  2. News
  3. CLNN

Clene Inc - CLNN STOCK NEWS

Welcome to our dedicated news page for Clene (Ticker: CLNN), a resource for investors and traders seeking the latest updates and insights on Clene.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clene's position in the market.

News
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN) reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8® in the RESCUE ALS open-label extension trial. The company also announced a statistically significant long-term survival benefit of 70% decreased risk of death associated with CNM-Au8 treatment in the HEALEY ALS Platform Trial. Additionally, they were awarded a $45.1 million NINDS grant to support research and expanded access of CNM-Au8 in people living with ALS and announced a peer-reviewed publication characterizing CNM-Au8 neuroprotective mechanism of action in a nanotechnology-focused journal. Clene's cash and cash equivalents totaled $42.1 million as of September 30, 2023, and they expect their resources to be sufficient to fund operations into the third quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
earnings
-
News
National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS
Rhea-AI Summary
Clene Inc. receives a $45.1 million grant from NINDS to support an Expanded Access Protocol for its investigational drug, CNM-Au8, in ALS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.2%
Tags
none
-
News
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
Rhea-AI Summary
Clene Inc. announces the publication of a scientific paper describing the catalytic mechanism of action of its drug CNM-Au8 in neurodegenerative diseases. CNM-Au8 treatment promotes cell survival and preservation of neurite networks. The drug is being investigated as a potential first-in-class treatment for ALS, MS, and PD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.66%
Tags
none
News
Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
Rhea-AI Summary
Clene Inc. (CLNN) to participate in Cantor Fitzgerald Annual Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.22%
Tags
conferences
-
News
Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
Rhea-AI Summary
Clene Inc. announces long-term follow-up data for patients treated with CNM-Au8 30mg in the HEALEY ALS Platform Trial, showing improved survival with a 49% decreased risk of death compared to PRO-ACT placebo (p=0.046). Pooled analysis with RESCUE-ALS Trial shows a 59% decreased risk of death (p=0.004). No safety signals observed with over 500 patient years of CNM-Au8 treatment exposure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
News
Clene to Present at Upcoming September Conferences
Rhea-AI Summary
Clene Inc. (Nasdaq: CLNN) to participate in investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.04%
Tags
conferences
News
Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up
Rhea-AI Summary
Clene Inc. announces significant survival benefit and decreased risk of ALS worsening events with CNM-Au8 treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
none
-
News
Clene Reports Second Quarter 2023 Financial Results and Operating Highlights
Rhea-AI Summary
Clene Inc. (CLNN) announced significant reductions in plasma neurofilament light chain levels compared to placebo in patients treated with CNM-Au8 in the HEALEY ALS Platform trial. The company also reported results of the Phase 2 RESCUE ALS study and its open-label extension, as well as a grant from the National Multiple Sclerosis Society to fund Cohort 2 of REPAIR-MS, a Phase 2 clinical study. Clene expects multiple near-term data announcements to support the benefit and safety of CNM-Au8 in ALS patients. The company's cash, cash equivalents, and marketable securities total $49.2 million as of June 30, 2023, including gross proceeds of $40 million from a recent public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
earnings
-
News
Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
conferences
News
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Stock CLNN logo
Clene Inc

Nasdaq:CLNN

CLNN Rankings

#4788 Ranked by Market Cap
#4857 Ranked by Stock Gains
N/A Ranked by Dividends

CLNN Stock Data

46.20M
67.91M
40.13%
19.28%
0.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Salt Lake City

About CLNN

clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.